BC
NKTR icon

Burleson & Co’s Nektar Therapeutics NKTR Stock Holding History

Burleson & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-107
Closed -$32K – 388
2021
Q1 		$32K Sell
107
-7,075
-99% -$2.2M 0.01% 207
2020
Q4 		$1.83M Buy
7,182
+993
+16% +$257K 0.32% 55
2020
Q3 		$1.62M Buy
6,189
+1,400
+29% +$440K 0.31% 61
2020
Q2 		$1.57M Buy
4,789
+1,500
+46% +$468K 0.34% 58
2020
Q1 		$1.02M Buy
3,289
+1,529
+87% +$473K 0.27% 72
2019
Q4 		$584K Sell
1,760
-232
-12% -$67.3K 0.16% 93
2019
Q3 		$501K Buy
1,992
+1,107
+125% +$406K 0.17% 81
2019
Q2 		$414K Buy
885
+193
+28% +$96.8K 0.17% 78
2019
Q1 		$334K Buy
692
+219
+46% +$130K 0.14% 86
2018
Q4 		$286K Buy
473
+33
+8% +$19.9K 0.15% 86
2018
Q3 		$251K Buy
+440
New +$376K 0.14% 90

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Burleson & Co's NKTR Position: Q2 2021 in Review

Burleson & Co sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 107 shares — an estimated $32K sold.

Burleson & Co first reported a position in NKTR in Q3 2018 and held it in 11 quarters. The position peaked at $1.83M in Q4 2020. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

  • Burleson & Co reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Burleson & Co sold 107 Nektar Therapeutics shares in Q2 2021, an estimated $32K.
  • Burleson & Co first reported a position in Nektar Therapeutics in Q3 2018 and held it in 11 quarters.
  • Burleson & Co's Nektar Therapeutics position peaked at $1.83M in Q4 2020.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on Burleson & Co's 13F filing for Q2 2021, filed 22 Jul 2021.